GLP-1 weight loss drugs are creating a new multi-billion dollar market for medical aesthetics.
The success of GLP-1s has led to billions in pharma revenue and millions of people losing weight.
It's also created a knock-on economy that no one has been building for yet.
Rapid GLP-1 weight loss can cause skin laxity, facial volume loss and visible tissue deflation across the body.
This is because the weight comes off faster than the skin and underlying tissue can adjust.
The existing treatments were developed decades ago for an entirely different purpose.
Hyaluronic-acid fillers add one millilitre of volume at a time, and biostimulators encourage collagen production. Neither was ever intended for larger-scale tissue regeneration.
A massive demand wave is coming for an opportunity pharma companies have not been building for.
Boston Consulting Group's estimate of provider revenue from treating post-GLP-1 aesthetic concerns.
Conexeu Sciences (NASDAQ: CNXU) has been doing preclinical university research in this area for over 10 years.
The CXU platform is an investigational extracellular-matrix platform designed to support soft-tissue restoration across aesthetics and wound care.
A different paradigm for regenerating tissue.
Injected as a fluid.
Remains liquid at room temperature and flows through a fine-gauge needle.
Sets in situ in roughly 10 minutes.
Thermosensitive: it forms a stable gel at body temperature.
Host tissue populates it.
Designed for cells and vessels to migrate in and remodel the matrix over time.
There is suddenly a massive need for regenerative aesthetic treatments that can be used for large volumes.
Traditional hyaluronic-acid fillers primarily add material to replace volume and were meant to be used in small-volume placements.
Conexeu Sciences’ CXU platform is hitting important preclinical milestones that validate potential treatments and applications.
Facial restoration.
Study objectives met in a small-volume cheek model, demonstrating tissue restoration within the parameters established for the study.
Large-volume restoration.
Study objectives met in a 200cc equivalent model, demonstrating tissue restoration at volumes relevant to potential future applications.
Injectable performance.
CXU met predefined benchmarks for being injected through a fine-gauge needle.
GLP-1 weight loss drugs are still in the early phases of a massive growth phase.
There are clear indicators that the adoption of GLP-1 weight loss drugs is creating a new boom in medical aesthetics.
McKinsey publicly stated in a research report that 63% of patients seeking facial aesthetics after GLP-1 weight loss were not previously active users of medical aesthetic treatments.
Flemming OrnskovChief Executive Officer of GaldermaWe do see the increasing penetration of GLP-1 treatments as an opportunity for injectable aesthetics.
Botox began as a treatment for rare eye-muscle disorders before expanding into aesthetics and becoming the product that defined the neuromodulator category.
Botox Cosmetic and Botox Therapeutic generate approximately $5.9 billion in annual revenue for AbbVie (FY2025).
That anchors a neuromodulator category worth an estimated $9–12 billion.
A new aesthetic category may similarly be being created around GLP-1 weight loss.
Rapid weight reduction can leave patients with loose skin, facial hollowing and significant tissue-volume loss. Yet the leading aesthetic injectables were developed more than 20 years ago for filling and collagen stimulation, not for large-volume tissue restoration.
Miles HarrisonChief Executive Officer of Conexeu SciencesEvery major category in injectable aesthetics was defined by a first mover, and we intend to be the next. This milestone is a concrete step toward establishing bioregeneration as the fourth category in injectable aesthetics, taking CXU™ from ambition to execution.
One platform with multiple meaningful applications.
One formulation, one device, designed by the company to scale across addressable markets without reformulation.
A single intellectual-property foundation.
A planned FDA 510(k) submission in Q1 2027.
Conexeu intends to first pursue a predicate-based pathway in wound care. The company sees initial wound-care clearance as a potential regulatory foundation for developing the CXU™ platform in additional applications.
P.R.O.O.F.™ program completed
12-month preclinical program met its pre-defined objectives.
Manufacturing & regulatory preparation
Scale-up and submission groundwork ahead of filing.
Wound-care 510(k) submission
Predicate-based pathway. Timing is a company target, not a certainty.
Potential expansion
Additional indications, subject to required development and regulatory authorization.
A 510(k) submission is a filing, not a clearance. The FDA may decline to accept the submission as filed, request additional data, or determine the device is not substantially equivalent to its predicate. No assurance can be given that clearance will be obtained or that the submission will occur in the anticipated timeframe.
Conexeu Sciences (NASDAQ: CNXU)
- Market cap
- $109.5M
- Shares outstanding
- 28.21M As of Sep 10, 2026
- Public float
- 15.54M
- Insider ownership
- 38.5%
- Avg. daily volume (9 days)
- 192K
- Listed
- Nasdaq Capital Market · May 21, 2026
Sources: Conexeu Sciences Form 10-Q (quarter ended July 31, 2026) and other company filings (shares, float, ownership); Twelve Data (prices, updated after each trading day).
Conexeu Sciences is uniquely positioned for the supercycle of GLP-1 weight loss drugs changing medical aesthetics.
- 1
Adoption continues to meaningfully scale
GLP-1 use among U.S. adults rose from 3% to 11% in just two years
- 2
A new unmet demand for restoring tissue
Facial hollowing, loose skin and lost tissue volume has created a new patient demand that existing treatments are not meant to serve
- 3
Lack of innovation in medical aesthetics
Most medical aesthetic treatments are still narrowly focused on small-volume products and have not been purpose built for the knock-on effects of GLP-1 adoption
- 4
One formulation to scale across multiple different markets
Conexeu Sciences’ CXU platform is designed to potentially be used in injectables, implants, burns, wound care and tissue scaffolds without reformulation
- 5
An expedited regulatory pathway
The FDA 510(k) submission pathway could provide Conexeu Sciences a potential regulatory foundation for further applications of the CXU platform
Disclaimer
The New Money provides background information on early-stage companies from publicly available sources. The New Money provides no advice on dealing in securities, is not a financial adviser and does not hold itself out to be a financial or investment adviser. This message is meant for information and educational purposes only. The information contained in this message has not been independently verified for accuracy or completeness. Anyone interested in obtaining financial and other information on companies mentioned in this message is advised to obtain such information directly from the companies, or from their own investment adviser. The New Money does not intend for this information to be used to inform an investment decision.
The New Money has been compensated by Conexeu Sciences in the amount of two hundred ten thousand common shares of the company for a media campaign running from June 1, 2026 to October 31, 2026, which may affect our ability to be unbiased. Because The New Money is compensated to provide this coverage, the information presented is inherently one-sided and should not be considered balanced or objective. We may have long or short positions in the securities of any of the companies mentioned. We therefore stress that you should conduct extensive independent due diligence as well as seek the advice of your financial advisor or a registered broker-dealer before investing in any securities.
The New Money is not, and does not act as, an investment adviser, broker-dealer, or securities analyst, and is not registered with the U.S. Securities and Exchange Commission (SEC), the Financial Industry Regulatory Authority, Inc. (FINRA), any other federal or any state securities or other regulatory authority and therefore does not provide investing advice or investment recommendations. This communication should not be used as a basis for making any investment. Investing is inherently risky. You must be aware of the risks and be willing to accept them in order to invest in any type of security, including the risk of losing your entire investment. This message is neither a solicitation nor an offer to buy or sell securities. No representation is being made that any stock trade will or is likely to achieve profits. Comparisons made to other featured companies or past performance are not indicative of future results.
The markets and trends that matter, made simple.
Join 100,000 investors reading The New Money
Research, not investment advice. The CXU platform is investigational.